As Australia's medicinal cannabis industry continues to evolve, healthcare professional education remains fundamental to its integration into mainstream healthcare. While patient access has expanded significantly since legalisation in 2016, translating scientific research into confident, evidence-based clinical practice continues to present challenges.
In part one of our two-part interview, we speak with Pavel, co-founder of Medihuanna, about the origins of the education platform, the barriers to integrating medicinal cannabis into modern medicine, and the importance of bridging the gap between emerging research and everyday clinical application.
1. Medihuanna was founded back in 2017 when the industry was just starting out. What gap in the market did you see that led you to co-found Medihuanna, and why was healthcare professional education specifically the right entry point?
When medicinal cannabis was legalised in Australia in 2016, there was growing interest from patients, advocates and the emerging industry. However, very few doctors had the knowledge, confidence or practical support needed to prescribe it. Alongside Dr Teresa Towpik, one of Australia's early authorised prescribers of medicinal cannabis, we recognised a significant gap between regulatory access and clinical practice. While scientific information was available, there was a lack of clear, accessible and practical education to help doctors understand cannabinoid medicines and confidently incorporate them into patient care.
The regulatory framework was also complex, with considerable administrative hurdles and uncertainty around prescribing pathways. Combined with the longstanding stigma surrounding cannabis, many doctors simply placed medicinal cannabis in the "too hard basket." We believed that if medicinal cannabis was going to gain recognition as a legitimate therapeutic option, healthcare professionals needed access to credible, evidence-based education delivered in a way that was relevant to everyday clinical practice.
We were also motivated by the challenges faced by patients living with chronic and complex conditions, many of whom were taking multiple medications and experiencing significant side effects. We saw the potential for medicinal cannabis, where clinically appropriate and supported by evidence, to offer an additional treatment option and, in some circumstances, help reduce reliance on other medicines. That's what inspired us to establish Medihuanna in 2017. Our vision was to create an accessible education platform that could reach healthcare professionals across Australia, bridge the gap between scientific research and clinical application, and give clinicians the knowledge and confidence to make informed prescribing decisions.
As the industry has evolved, another important challenge has emerged: navigating an increasingly complex product landscape. With so many medicinal cannabis products available, differences in cannabinoid composition, formulations, delivery methods and quality can make selecting an appropriate medicine challenging. We believe simplifying this process through independent education, reliable product information and practical clinical guidance is essential to supporting confident, evidence-based prescribing. Ultimately, our purpose has never been simply to encourage more medicinal cannabis prescriptions. It has been to help integrate cannabinoid medicines into modern healthcare, reduce stigma through education, and ensure patients can access safe, evidence-based treatment under the guidance of informed healthcare professionals.
2. You've described cannabis as a medicine that needs to be integrated into modern medicine, and that's a big part of Medihuanna's purpose. What does that integration look like day to day, and where does it most often stall?
For me, integrating medicinal cannabis into modern medicine means approaching it with the same clinical standards, professional responsibilities and evidence-based decision-making that we apply to any other treatment. In practice, that starts with a comprehensive patient assessment, understanding the available evidence, identifying potential contraindications and drug interactions, and determining whether cannabinoid therapy is appropriate within an individualised treatment plan. It also means establishing clear therapeutic goals, documenting clinical decisions, monitoring treatment outcomes and knowing when treatment should be adjusted or discontinued.
Where integration often stalls is in the transition from theoretical knowledge to practical clinical confidence. A healthcare professional might understand the pharmacology of THC and CBD but still feel uncertain about patient selection, formulation differences, dosing and titration, or how to navigate the regulatory requirements.
Another challenge is the fragmentation of the medicinal cannabis landscape. There are numerous products, evolving evidence and different prescribing requirements across jurisdictions. That complexity can make it difficult for clinicians to incorporate cannabinoid therapy into their existing workflows. I believe genuine integration will occur when medicinal cannabis is no longer treated as a separate or exceptional area of medicine, but as a therapeutic option that can be critically evaluated, appropriately prescribed and monitored within established clinical practice.
3. You've previously talked about "bridging the gap between research and clinical application" – what does that bridge-building look like day to day, and where does it break down most often?
One of the biggest challenges in medicinal cannabis is that scientific research, clinical experience and everyday prescribing practice don't always develop at the same pace. New research is continually emerging, but interpreting that evidence and understanding its relevance to individual patients can be challenging, particularly when studies use different cannabinoid formulations, doses, administration methods and patient populations.
At Medihuanna, bridging that gap means bringing researchers, experienced clinicians and healthcare professionals together to examine the evidence in a practical clinical context. Through our educational webinars, case-based discussions, and accredited professional development activities, we explore not just what the research tells us, but what it means for clinical decision-making.
For example, rather than simply discussing the pharmacology of a cannabinoid, we aim to explore how that knowledge relates to patient selection, potential therapeutic benefits, safety considerations and monitoring treatment outcomes.
Where the bridge most often breaks down is in translating emerging scientific findings into clinically meaningful guidance. Promising preclinical research doesn't necessarily translate into demonstrated patient benefit, and the evidence supporting one formulation or indication cannot automatically be applied to another. I think education providers have an important responsibility to communicate these distinctions clearly. Our role isn't to promote medicinal cannabis as a solution for every patient, but to help clinicians understand where the evidence is strong, where uncertainty remains and how to make informed decisions within those limitations.
Ultimately, the goal is to move beyond simply sharing information towards developing clinical competence and confidence.
As Pavel highlights, the future of medicinal cannabis in Australia depends on more than increasing access. Building clinical confidence, strengthening prescribing practices and ensuring healthcare professionals have access to credible, independent education are essential to supporting better patient outcomes. In part two, we explore how medicinal cannabis education must evolve alongside Australia's regulatory landscape, and what lessons can be drawn from international markets to support the next phase of industry development.
Visit the Medihuanna website and their Linkedin profile to learn more about their comprehensive educational platform.
Learn More
EQWELLIBRIYUM offers end-to-end consulting for organisations navigating the medicinal cannabis market in Australia. With strategic insights and operational frameworks that are designed to help you thrive, we’re here to help you. Learn more by contacting us today at hello@eqwellibriyum.com or signing up to our email list below.